There are numerous scientific trials published in notable clinical peer-reviewed journals or presented at international medical meetings, highlighting the effectiveness of Rosehip with GOPO® , THE PATENTED COMPOUND:
PHYTOMEDICINE 2010 – Rosehip has been the subject of a significant new study published in the of medical journal Phytomedicine – Rosehip herbal remedy in patients with Rheumatoid Arthritis – a randomised controlled trial – which has shown that patients with Rheumatoid Arthritis may benefit from additional treatment with Rosehip powder with Galactolipid (GOPO®).
APLAR 2008 – a presentation by Joseph Schwager, Phd, at the APLAR conference Asia Pacific League of Associations for Rheumatology conference in Japan titled The Galactolipid GOPO® Mediates Beneficial Effects of Rose Hip on Arthritis by Reducing Chemokine and Interleukin Production in Macrophages and Chondrocytes, showed that an active compound, when isolated from the Rosehip, may play a role in assisting in the rebuilding and protection of cartilage
OARSI 2008 – A study released by Arasalan Kharazmi, Phd, at OARSI (Osteoarthritis Research Society International) – Laboratory and preclinical studies on the anti-inflammatory and anti-oxidant properties of rosehip powder – Identification and characterisation of the active component GOPO® – demonstrate through assessment of in vitro studies that rosehip powder exhibits anti-inflammatory as well as anti-oxidant activities.
JOURNAL OF RHEUMATOLOGY 2005 – A trial published in the Scandinavian Journal of Rheumatology – A Powder made from seeds and shells of Rosehip Subspecies (Rosa Canina L) reduces the symptoms of Knee and Hip Osteoarthritis: a Randomised, Double-Blind, Placebo Controlled Trial – showed that 82% of patients reported a reduction in pain after 3 weeks of active treatment with GOPO®. Pain was alleviated to such an extent that 40% reduced their consumption of parecetamol1
Further evidence of the effectiveness of GOPO® on chronic joint conditions has been reported by the Phytomedicine Journal of 2004; 66% of patients taking GOPO® reported a reduction in joint pain. Interestingly, patients also reported an improvement in general wellbeing, including mood, sleep quality and energy.
For a full set of scientific studies and presentations see our Scientific Research page.